Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768301 | 1.00 | PRCP (0.68) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL16455043 | 1.00 | PRCP (0.68) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL10226238 | 1.00 | PRCP (0.68) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL1009943 | 0.86 | PRCP (0.64) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL13977536 | 0.83 | PRCP (0.67) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL27985631 | 0.83 | PRCP (0.60) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL6429588 | 0.82 | PRCP (0.59) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL10434781 | 0.81 | PRCP (0.65) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL1717271 | 0.81 | PRCP (0.65) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL4020963 | 0.81 | PRCP (0.65) | PRCPSLC22A1OPRM1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| CN-114671807-A | Preparation method of 1-substituted isoquinoline compound | 联化科技（德州）有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
| EP-3793550-A2 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-03-24 | — | — | EP | disclosed |
| EP-3772513-A1 | SHP2 INHIBITORS | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2021-02-10 | — | — | EP | disclosed |
| US-20180110791-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2018-04-26 | — | — | US | disclosed |
| CN-104327046-B | Triazole N ethyl tetrahydroisoquinolicompounds compounds and its preparation method and application | 中国药科大学 | 2017-11-17 | — | — | CN | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| EP-0983244-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050364-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| US-5686458-A | Quinazoline deriviates for treating peptic ulcer | YUHAN CORPORATION (KR) | 1997-11-11 | — | — | US | disclosed |
| EP-0677049-A1 | QUINAZOLINE DERIVATIVES | YUHAN CORPORATION, LTD. (KR) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994014795-A1 | QUINAZOLINE DERIVATIVES | YUHAN CORPORATION (KR) | 1994-07-07 | — | — | WO | disclosed |
| EP-0230871-B1 | HALOACYL 1-SUBSTITUTED-1,2,3,4-TETRAHYDROISOQUINOLINES AS HERBICIDE ANTIDOTES | Monsanto Company (US) | 1993-09-22 | — | — | EP | disclosed |
| US-4755218-A | Reducing acetochlor injury to corn by applying with antidote | MONSANTO COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
| EP-0230871-A2 | Haloacyl 1-substituted-1,2,3,4-tetrahydroisoquinolines as herbicide antidotes | Monsanto Company (US) | 1987-08-05 | — | — | EP | disclosed |
| US-4062961-A | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES | SMITHKLINE CORPORATION (US) | 1977-12-13 | — | — | US | disclosed |
| US-3988339-A | 7 OR 8-SUBSTITUTED 1,2,3,4-TETRAHYDRO-ISOQUINOLINE | SMITHKLINE CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110791-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PRCP 44/4885SLC22A1 2499/4885OPRM1 4351/4885 |
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HMBS | PRCP 1432/4885SLC22A1 2180/4885OPRM1 4429/4885 |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | PRCP 2585/4885SLC22A1 3721/4885OPRM1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.